Commentary: journals must facilitate the dissemination and scrutiny of clinical researchBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c5397 (Published 12 October 2010) Cite this as: BMJ 2010;341:c5397
- Nick Freemantle, professor of clinical epidemiology and biostatistics
- 1School of Health and Population Sciences, Edgbaston, Birmingham B15 2SP, UK
- Correspondence to:
Steinbrook and Kassirer’s analysis article (doi:10.1136/bmj.c5391)—which suggests that medical journals should require full access to data for industry sponsored trials—broaches many questions, but it is not clear that it advances our thinking. The first question raised is whether the authors truly comprehend the nature of large scale randomised trials. Trials are a major industry; complex, costly, and bureaucratic. Good chairs of steering committees do check carefully that things are done properly, at least to the extent that they are able, but such scrutiny is fundamentally, in the context of drug development and safety, the responsibility of the regulators.
The RECORD trial1 suffered from a number of methodological challenges, in particular unacceptably high levels of loss to follow-up.2 It is not surprising that some of the judgments of a blinded endpoints committee were contestable. The reason we have such committees is because a simple algorithm …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial